Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Holding EVO?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.05Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: -7.86%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call reflects a company undergoing significant transformation to address challenging market conditions and operational inefficiencies. While there are strong partnerships and growth in specific segments like Just-Evotec Biologics, declining revenues in shared R&D and market uncertainties pose challenges. The strategic reset aims to position Evotec for future growth, but immediate impacts are still unfolding.Company Guidance
In the Evotec SE Capital Market Briefing Conference Call for the third fiscal period of 2024, the company provided guidance with several key metrics. Group revenues for the full year 2024 are expected to range between €790 million and €820 million. The company aims to reduce R&D expenditure to €50 million to €60 million for the year, focusing on impactful platforms. Evotec is targeting an adjusted EBITDA of €15 million to €35 million, highlighting a path towards profitability despite challenging market conditions. The Priority Reset initiative is on track to deliver €40 million in annual savings by 2025, with cost optimization measures already implemented. The company also reported a positive free cash flow of €16.7 million in Q3, reflecting improved cash management strategies.Expansion of Strategic Partnerships
Evotec has expanded its collaborations with major partners, including Sandoz, Novo Nordisk, and BMS, enhancing its order book and visibility for future revenue.
Just-Evotec Biologics Revenue Growth
The Just-Evotec Biologics segment experienced a 74% increase in revenue compared to the previous year, driven by cooperation with Sandoz and other partners.
Improved Cash Management
Evotec has made significant progress in cash management, resulting in a positive free cash flow of €16.7 million for Q3, reversing a negative trend from earlier quarters.
Cost Optimization on Track
The priority reset program is on track to deliver €40 million in annual savings, with over 60% of targeted impacts already implemented.
---
EVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $4.58 | $3.86 | -15.72% |
| Aug 14, 2024 | $3.32 | $3.31 | -0.30% |
| May 22, 2024 | $5.09 | $5.17 | +1.57% |
| Apr 24, 2024 | $7.65 | $5.23 | -31.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evotec AG (EVO) report earnings?
Evotec AG (EVO) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Evotec AG (EVO) earnings time?
Evotec AG (EVO) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVO EPS forecast?
EVO EPS forecast for the fiscal quarter 2024 (Q4) is -0.02.
---